These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 7155241)

  • 21. [Relation of serum erythropoietin concentration to erythropoiesis in different chronic kidney diseases and stages of kidney failure].
    Jahn CH
    Wien Klin Wochenschr; 1993; 105(11):327-9. PubMed ID: 8333200
    [No Abstract]   [Full Text] [Related]  

  • 22. Soluble ELAM-1 is elevated with the progression of IgA nephropathy but not with that of polycystic kidney disease.
    Hotta O; Taguma Y; Yusa N; Kitamura H; Sudo K; Horigome I
    Nephron; 1996; 72(4):736-8. PubMed ID: 8730465
    [No Abstract]   [Full Text] [Related]  

  • 23. Renal developmental diseases.
    Avner ED
    Semin Nephrol; 1993 Sep; 13(5):427-35. PubMed ID: 8210806
    [No Abstract]   [Full Text] [Related]  

  • 24. Serum immunoreactive erythropoietin levels in patients with polycystic kidney disease as compared with other hemodialysis patients.
    Chandra M; Miller ME; Garcia JF; Mossey RT; McVicar M
    Nephron; 1985; 39(1):26-9. PubMed ID: 3969187
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Behavior of erythropoietin serum level in various kidney diseases].
    Heilmann E
    Verh Dtsch Ges Inn Med; 1973; 79():451-3. PubMed ID: 4597612
    [No Abstract]   [Full Text] [Related]  

  • 26. Blood pressure control key in polycystic kidney disease.
    Shields J; Maxwell AP
    Practitioner; 2008 Feb; 252(1703):22, 25-6, 29. PubMed ID: 18426156
    [No Abstract]   [Full Text] [Related]  

  • 27. Effect of moderate protein restriction on the rate of progression of chronic renal failure.
    Hannedouche T; Chauveau P; Fehrat A; Albouze G; Jungers P
    Kidney Int Suppl; 1989 Nov; 27():S91-5. PubMed ID: 2636679
    [No Abstract]   [Full Text] [Related]  

  • 28. Renin secretion in patients with various nephropathies and coexistent arterial hypertension.
    Kuska J; Kokot F; Drobisz M; Drab M
    Mater Med Pol; 1986; 18(4):218-24. PubMed ID: 3302551
    [No Abstract]   [Full Text] [Related]  

  • 29. An update on the effects of conjugated linoleic acid (CLA) in a rodent model of polycystic kidney disease.
    Khan SA
    Acta Pol Pharm; 2011; 68(4):609-10. PubMed ID: 21796945
    [No Abstract]   [Full Text] [Related]  

  • 30. Apoptosis: potential role in renal diseases.
    Menè P; Amore A
    Nephrol Dial Transplant; 1998 Aug; 13(8):1936-43. PubMed ID: 9719144
    [No Abstract]   [Full Text] [Related]  

  • 31. [Ambulatory 24-hour blood pressure monitoring of children and young adults with autosome dominant polycystic kidney degeneration].
    Geberth S; Zeier M; Schmidt KG; Mandelbaum A; Ritz E
    Z Kardiol; 1992; 81 Suppl 2():21-4. PubMed ID: 1514306
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group.
    Klahr S; Levey AS; Beck GJ; Caggiula AW; Hunsicker L; Kusek JW; Striker G
    N Engl J Med; 1994 Mar; 330(13):877-84. PubMed ID: 8114857
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Early arterial stiffness and inflammatory bio-markers in normotensive polycystic kidney disease patients.
    Kocyigit I; Kaya MG; Orscelik O; Kaya C; Akpek M; Zengin H; Sipahioglu MH; Unal A; Yilmaz MI; Tokgoz B; Oymak O; Axelsson J
    Am J Nephrol; 2012; 36(1):11-8. PubMed ID: 22699414
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Incidence of erythrocyte fragmentation in nephropathies].
    Dami R; Rudhardt M
    Schweiz Med Wochenschr; 1974 Feb; 104(5):170-7. PubMed ID: 4812347
    [No Abstract]   [Full Text] [Related]  

  • 35. Failure of blood pressure to increase following erythropoietin therapy in the renoprival status.
    De Santo NG; Manzo M; Raiola P; Lanzetti N; Capasso G; Ficociello R; Anastasio P; Esposito R
    Int J Artif Organs; 1992 Mar; 15(3):144-6. PubMed ID: 1521898
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Role of cardiac output in the development of the hypertensive syndrome in chronic parenchymal diseases of the kidneys].
    Sumarokov AV; Mikhaĭlov AA; Danil'chenko MA
    Kardiologiia; 1971 Oct; 11(10):65-9. PubMed ID: 4944891
    [No Abstract]   [Full Text] [Related]  

  • 37. Polycystic kidney disease and the flyer.
    Rayman RB
    Aviat Space Environ Med; 1985 Nov; 56(11):1105-6. PubMed ID: 4074266
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Polycystic kidney disease: will it become treatable?
    Gross P
    Pol Arch Med Wewn; 2008 May; 118(5):298-301. PubMed ID: 18619180
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Spongy medullary degeneration of the kidney and folowed by secondary hyperparathyroidism].
    Fried L; Magyarsoki F; Szilagyi G
    Z Urol Nephrol; 1968 Jul; 61(7):443-51. PubMed ID: 5729498
    [No Abstract]   [Full Text] [Related]  

  • 40. Screening for kidney diseases: older measures versus novel biomarkers.
    Wu I; Parikh CR
    Clin J Am Soc Nephrol; 2008 Nov; 3(6):1895-901. PubMed ID: 18922990
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.